{"id":1292,"date":"2025-11-27T15:48:11","date_gmt":"2025-11-27T14:48:11","guid":{"rendered":"https:\/\/lensounds.com\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/"},"modified":"2025-11-27T15:48:11","modified_gmt":"2025-11-27T14:48:11","slug":"development-of-psma-targeted-alpha-therapy-using-211atpsma-5","status":"publish","type":"science","link":"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/","title":{"rendered":"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5"},"content":{"rendered":"<h2>Abstract<\/h2>\n<p>This comprehensive review describes the development of [<sup>211<\/sup>At]PSMA-5, a cyclotron-produced alpha-particle\u2013emitting radiopharmaceutical for targeted therapy of metastatic castration-resistant prostate cancer (mCRPC). The article covers <sup>211<\/sup>At production via the <sup>209<\/sup>Bi(\u03b1,2n)<sup>211<\/sup>At reaction, radiosynthesis of [<sup>211<\/sup>At]PSMA-5 with radiochemical yields exceeding 60%, and comprehensive preclinical evaluation demonstrating superior cytotoxicity compared to [<sup>225<\/sup>Ac]PSMA-617. Biodistribution studies in mice and cynomolgus monkeys revealed high tumor uptake with favorable kinetics and excellent in vivo stability. Toxicology studies supported clinical translation with no severe toxicities identified up to 35 MBq\/kg. The first-in-human Phase I trial (NCT06441994) at the University of Osaka Hospital, which began in May 2024, is enrolling 15 patients with mCRPC. To date, nine patients have been treated, with promising therapeutic effects observed at the third dose level. The development of [<sup>211<\/sup>At]PSMA-5 represents a significant advance in sustainable, cyclotron-based alpha therapy with potential to address patients refractory to current standard-of-care treatments.<\/p>\n<h2>Publication Information<\/h2>\n<p><strong>Journal:<\/strong> Seminars in Nuclear Medicine<\/p>\n<p><strong>Volume:<\/strong> 55, Issue 6<\/p>\n<p><strong>Pages:<\/strong> 947-954<\/p>\n<p><strong>Publication Date:<\/strong> November 2025<\/p>\n<p><strong>DOI:<\/strong> 10.1053\/j.semnuclmed.2025.09.005<\/p>\n<p><strong>Journal Link:<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0001299825001205?via%3Dihub\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0001299825001205?via%3Dihub<\/a><\/p>\n<h2>Authors<\/h2>\n<p>Takahiro Watabe, Satoru Naka, Yuri Shirakami, Kazuki Kaneda, Masatoshi Murakami, Akira Toyoshima, J\u00f6rg Cardinale, Frederik L. Giesel<\/p>\n<p><strong>Institutional Affiliations:<\/strong> University of Osaka Hospital, Fukushima Medical University, RIKEN Nishina Center for Accelerator-Based Science, Research Center for Nuclear Physics (RCNP), University of Osaka, Japan; University of Heidelberg, Germany<\/p>\n<p><strong>Funding:<\/strong> AMED translational research grant (Seeds-F) (Grant Number: JP23ym0126091)<\/p>\n<p><strong>Associated Clinical Trial:<\/strong> NCT06441994 (15 patients with mCRPC, estimated completion March 2027)<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Watabe, T.; Naka, S.; Shirakami, Y.; Kaneda, K.; Murakami, M.; Toyoshima, A.; Cardinale, J.; Giesel, F.L. Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5. Seminars in Nuclear Medicine 2025;55(6):947-954. DOI: 10.1053\/j.semnuclmed.2025.09.005<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"science_category":[49],"class_list":["post-1292","science","type-science","status-publish","hentry","science_category-at-211-publications"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5 - Atonco<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5 - Atonco\" \/>\n<meta property=\"og:description\" content=\"Watabe, T.; Naka, S.; Shirakami, Y.; Kaneda, K.; Murakami, M.; Toyoshima, A.; Cardinale, J.; Giesel, F.L. Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5. Seminars in Nuclear Medicine 2025;55(6):947-954. DOI: 10.1053\/j.semnuclmed.2025.09.005\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\\\/\",\"name\":\"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5 - Atonco\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"datePublished\":\"2025-11-27T14:48:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5 - Atonco","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/","og_locale":"en_US","og_type":"article","og_title":"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5 - Atonco","og_description":"Watabe, T.; Naka, S.; Shirakami, Y.; Kaneda, K.; Murakami, M.; Toyoshima, A.; Cardinale, J.; Giesel, F.L. Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5. Seminars in Nuclear Medicine 2025;55(6):947-954. DOI: 10.1053\/j.semnuclmed.2025.09.005","og_url":"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/","og_site_name":"Atonco","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/","url":"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/","name":"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5 - Atonco","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"datePublished":"2025-11-27T14:48:11+00:00","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/science\/development-of-psma-targeted-alpha-therapy-using-211atpsma-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/atonco-pharma.com\/en\/science\/"},{"@type":"ListItem","position":3,"name":"Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science\/1292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/science"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1292"}],"wp:term":[{"taxonomy":"science_category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science_category?post=1292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}